Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

YVONNE M SAENGER

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1235363664
CMS profile
328717
Location
NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$10,203.40

9 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $10,035.50 4
Food and Beverage $167.90 5

By paying entity

PY2024 · entire year · sorted by reported total

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

YVONNE M SAENGER

NPI 1235363664 · CMS profile ID 328717

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1235363664?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
YVONNE M SAENGER, NPI 1235363664, CMS profile ID 328717. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1235363664?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). YVONNE M SAENGER, NPI 1235363664, CMS profile ID 328717. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1235363664?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
YVONNE M SAENGER, NPI 1235363664, CMS profile ID 328717, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1235363664?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

9 matching records · $10,203.40 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 9 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–9 of 9.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $32.8308/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087333599 CMS
Novartis Pharmaceuticals Corporation $33.7207/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087333587 CMS
Novartis Pharmaceuticals Corporation $32.8306/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087333585 CMS
Genentech USA, Inc. $46.4906/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133136235 CMS
AstraZeneca Pharmaceuticals LP $525.0005/22/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104780964 CMS
Regeneron Pharmaceuticals, Inc. $413.5001/26/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114404471 CMS
Regeneron Pharmaceuticals, Inc. $4,962.0001/26/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114404473 CMS
Regeneron Pharmaceuticals, Inc. $4,135.0001/26/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114404475 CMS
Aveo Pharmaceuticals, Inc. $22.0301/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143488810 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $49.43 3
PY2020 $2,400.00 1
PY2022 $72.16 1
PY2023 $201.45 2
PY2024 $10,203.40 9
PY2025 $231.51 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $693.33 2
PY2025 Principal investigator $175,671.23 49
PY2024 Principal investigator $347,199.39 43
PY2023 Principal investigator $35,106.77 9
PY2022 Principal investigator $38,669.88 6
PY2021 Principal investigator $321,229.19 8
PY2020 Principal investigator $387,598.50 6
PY2019 Principal investigator $205,955.99 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

43 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $4,119.00 12/23/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS No dispute reported 06/30/2026 1133383941
Principal investigator 1 Genentech, Inc. $2,531.25 12/11/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1133384091
Principal investigator 1 Genentech, Inc. $1,050.00 12/02/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS No dispute reported 06/30/2026 1133383949
Principal investigator 1 Genentech, Inc. $1,050.00 11/25/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS No dispute reported 06/30/2026 1133383953
Principal investigator 1 Genentech, Inc. $10,595.00 11/19/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS No dispute reported 06/30/2026 1133383951
Principal investigator 1 Genentech, Inc. $1,050.00 11/18/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1133384089
Principal investigator 1 Genentech, Inc. $1,050.00 11/15/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE of NY LLC
Morpheus NeoAdj HCC No dispute reported 06/30/2026 1133384107
Principal investigator 1 Genentech, Inc. $2,460.00 11/04/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS No dispute reported 06/30/2026 1133383945
Principal investigator 1 Genentech, Inc. $5,448.00 10/28/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS No dispute reported 06/30/2026 1133383943
Principal investigator 1 Genentech, Inc. $14,288.00 10/17/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS No dispute reported 06/30/2026 1133383947
Principal investigator 1 Genentech, Inc. $2,100.00 10/15/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE 3408
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1133383893
Principal investigator 1 Genentech, Inc. $3,796.00 10/01/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE 3408
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1133383895
Principal investigator 1 Genentech, Inc. $4,450.00 09/25/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS No dispute reported 06/30/2026 1133383937
Principal investigator 1 Genentech, Inc. $1,050.00 09/25/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1133384065
Principal investigator 1 Genentech, Inc. $650.00 09/25/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1133384073
Principal investigator 1 Genentech, Inc. $1,050.00 09/25/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1133384075
Principal investigator 1 Genentech, Inc. $750.00 09/25/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1133384081
Principal investigator 1 Genentech, Inc. $1,050.00 09/25/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1133384087
Principal investigator 1 Genentech, Inc. $2,767.50 09/23/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1133384077
Principal investigator 1 Genentech, Inc. $3,800.00 09/17/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS No dispute reported 06/30/2026 1133383939
Principal investigator 1 Genentech, Inc. $24,527.00 08/22/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS No dispute reported 06/30/2026 1133383935
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $871.76 08/15/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
CEMIPLIMAB SURVIVORSHIP EPIDEMIOLOGY (CASE) STUDY No dispute reported 06/30/2026 1082433724
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,825.00 08/08/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
CEMIPLIMAB SURVIVORSHIP EPIDEMIOLOGY (CASE) STUDY No dispute reported 06/30/2026 1082433464
Principal investigator 1 Genentech, Inc. $31,101.00 07/22/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS No dispute reported 06/30/2026 1133383933
Principal investigator 1 Genentech, Inc. $2,100.00 07/10/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF
Morpheus NeoAdj HCC No dispute reported 06/30/2026 1133383907
Principal investigator 1 Genentech, Inc. $6,900.00 06/26/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF
Morpheus NeoAdj HCC No dispute reported 06/30/2026 1133383897
Principal investigator 1 Genentech, Inc. $1,050.00 06/26/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1133384057
Principal investigator 1 Genentech, Inc. $327.00 06/20/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS No dispute reported 06/30/2026 1133383931
Principal investigator 1 Genentech, Inc. $10,200.00 05/28/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1133384051
Principal investigator 1 Genentech, Inc. $5,063.00 05/28/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1133384053
Principal investigator 1 Genentech, Inc. $37,373.00 05/28/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1133384055
Principal investigator 1 Genentech, Inc. $1,823.00 05/28/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1133384059
Principal investigator 1 Genentech, Inc. $1,050.00 05/23/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1133384061
Principal investigator 1 Genentech, Inc. $21,387.00 05/22/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS No dispute reported 06/30/2026 1133383929
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $435.88 05/02/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
CEMIPLIMAB SURVIVORSHIP EPIDEMIOLOGY (CASE) STUDY No dispute reported 06/30/2026 1082425591
Principal investigator 1 Genentech, Inc. $1,050.00 04/24/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF
Morpheus NeoAdj HCC No dispute reported 06/30/2026 1133383905
Principal investigator 1 Genentech, Inc. $10,200.00 04/10/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF
Morpheus NeoAdj HCC No dispute reported 06/30/2026 1133383899
Principal investigator 1 Genentech, Inc. $50,942.00 04/10/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF
Morpheus NeoAdj HCC No dispute reported 06/30/2026 1133383901
Principal investigator 1 Genentech, Inc. $750.00 04/10/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF
Morpheus NeoAdj HCC No dispute reported 06/30/2026 1133383903
Principal investigator 1 Genentech, Inc. $5,500.00 03/25/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1133384047
Principal investigator 1 Genentech, Inc. $54,459.00 02/05/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS No dispute reported 06/30/2026 1133383927
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,700.00 01/25/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
CEMIPLIMAB SURVIVORSHIP EPIDEMIOLOGY (CASE) STUDY No dispute reported 06/30/2026 1082415917
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $10,460.00 01/16/2024 Non-covered Recipient Entity
Brany - Biomedical Research Alliance Of New York
PhII 1L HCC Rela+Nivo+Bev vs Nivo+Bev - A Phase 1/2, Safety Confirmation, Placebo-controlled, Randomized Study of Nivolumab in Combination with Relatlimab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular Carcinoma No dispute reported 06/30/2026 1123476296